Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Mimedx (MDXG) over the last 15 years, with Q3 2025 value amounting to $27.6 million.

  • Mimedx's Accumulated Expenses rose 3708.48% to $27.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year increase of 3708.48%. This contributed to the annual value of $23.7 million for FY2024, which is 587.84% up from last year.
  • Mimedx's Accumulated Expenses amounted to $27.6 million in Q3 2025, which was up 3708.48% from $22.0 million recorded in Q2 2025.
  • Mimedx's Accumulated Expenses' 5-year high stood at $30.7 million during Q1 2021, with a 5-year trough of $17.1 million in Q1 2022.
  • Its 5-year average for Accumulated Expenses is $21.4 million, with a median of $21.3 million in 2021.
  • In the last 5 years, Mimedx's Accumulated Expenses crashed by 4424.96% in 2022 and then surged by 3708.48% in 2025.
  • Mimedx's Accumulated Expenses (Quarter) stood at $23.6 million in 2021, then decreased by 11.61% to $20.9 million in 2022, then grew by 7.18% to $22.4 million in 2023, then rose by 5.88% to $23.7 million in 2024, then increased by 16.83% to $27.6 million in 2025.
  • Its Accumulated Expenses was $27.6 million in Q3 2025, compared to $22.0 million in Q2 2025 and $18.7 million in Q1 2025.